DK3402811T3 - Egf(a)-analoger med fedtsyresubstituenter - Google Patents
Egf(a)-analoger med fedtsyresubstituenter Download PDFInfo
- Publication number
- DK3402811T3 DK3402811T3 DK17701078.2T DK17701078T DK3402811T3 DK 3402811 T3 DK3402811 T3 DK 3402811T3 DK 17701078 T DK17701078 T DK 17701078T DK 3402811 T3 DK3402811 T3 DK 3402811T3
- Authority
- DK
- Denmark
- Prior art keywords
- egf
- analogs
- fatty acid
- acid substitutes
- substitutes
- Prior art date
Links
- 235000014113 dietary fatty acids Nutrition 0.000 title 1
- 229930195729 fatty acid Natural products 0.000 title 1
- 239000000194 fatty acid Substances 0.000 title 1
- 150000004665 fatty acids Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016070791 | 2016-01-13 | ||
| CN2016076580 | 2016-03-17 | ||
| EP16195965 | 2016-10-27 | ||
| PCT/EP2017/050668 WO2017121850A1 (en) | 2016-01-13 | 2017-01-13 | Egf(a) analogues with fatty acid substituents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3402811T3 true DK3402811T3 (da) | 2022-06-13 |
Family
ID=57868232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17701078.2T DK3402811T3 (da) | 2016-01-13 | 2017-01-13 | Egf(a)-analoger med fedtsyresubstituenter |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10822385B2 (2) |
| EP (1) | EP3402811B1 (2) |
| JP (2) | JP6797926B2 (2) |
| KR (1) | KR102417487B1 (2) |
| CN (1) | CN108473550B (2) |
| AU (1) | AU2017207862B2 (2) |
| BR (1) | BR112018013820A2 (2) |
| CA (1) | CA3010756A1 (2) |
| CL (1) | CL2018001868A1 (2) |
| CO (1) | CO2018007440A2 (2) |
| DK (1) | DK3402811T3 (2) |
| ES (1) | ES2916998T3 (2) |
| HR (1) | HRP20220720T1 (2) |
| HU (1) | HUE058647T2 (2) |
| IL (1) | IL260043A (2) |
| LT (1) | LT3402811T (2) |
| MX (1) | MX2018008681A (2) |
| MY (1) | MY195199A (2) |
| PE (1) | PE20181376A1 (2) |
| PH (1) | PH12018501502A1 (2) |
| PL (1) | PL3402811T3 (2) |
| RS (1) | RS63298B1 (2) |
| RU (1) | RU2747877C2 (2) |
| SA (1) | SA518391996B1 (2) |
| SI (1) | SI3402811T1 (2) |
| WO (1) | WO2017121850A1 (2) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3402811T1 (sl) | 2016-01-13 | 2022-06-30 | Novo Nordisk A/S | Analogi EGF(A) z maščobnokislinskimi substituenti |
| SI3402782T1 (sl) | 2016-01-13 | 2020-11-30 | Grunenthal Gmbh | 8-amino-2-okso-1,3-diaza-spiro-(4,5)-dekanski derivati |
| CA3011176C (en) | 2016-01-13 | 2023-09-19 | Grunenthal Gmbh | 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives |
| CA3011180A1 (en) | 2016-01-13 | 2017-07-20 | Grunenthal Gmbh | 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives |
| SI3402784T1 (sl) | 2016-01-13 | 2020-07-31 | Gruenenthal Gmbh | Derivati 3-((hetero)aril)-alkil-8-amino-2-okso-1,3-diaza-spiro-(4.5)-dekana |
| MA49617A (fr) * | 2017-07-19 | 2020-05-27 | Novo Nordisk As | Analogues d'egf(a), préparation, formulations et utilisations associées |
| CA3068956A1 (en) | 2017-07-19 | 2019-01-24 | Novo Nordisk A/S | Bifunctional compounds |
| US11358994B2 (en) * | 2017-07-27 | 2022-06-14 | Saint Louis University | Fatty acid modified human epidermal growth factor |
| IL279363B2 (en) | 2018-06-21 | 2025-12-01 | Merck Sharp & Dohme | Pcsk9 antagonist compounds |
| WO2020070276A1 (en) | 2018-10-05 | 2020-04-09 | Novo Nordisk A/S | Bifunctional compounds comprising insulin peptides and egf(a) peptides |
| CA3131997A1 (en) | 2019-03-22 | 2020-10-01 | 3M Innovative Properties Company | Fall-protection system with monitoring system |
| CN110357969B (zh) * | 2019-05-27 | 2022-03-08 | 北京志道生物科技有限公司 | 一种GLP1-EGFa异源二聚体蛋白、功能及方法 |
| AU2020326265A1 (en) | 2019-08-07 | 2022-02-03 | Novo Nordisk A/S | Solid compositions comprising an EGF(A) derivative and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
| CN114641275A (zh) | 2019-11-07 | 2022-06-17 | 诺和诺德股份有限公司 | 包含pcsk9抑制剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物 |
| EP4076492A4 (en) | 2019-12-20 | 2024-01-17 | Merck Sharp & Dohme LLC | PCSK9 ANTAGONIST COMPOUNDS |
| JP2024527488A (ja) | 2021-07-02 | 2024-07-25 | スリーエム イノベイティブ プロパティズ カンパニー | 落下防止安全装置と連動される空中リフト |
| WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007022123A2 (en) | 2005-08-11 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
| JP2009510999A (ja) | 2005-07-29 | 2009-03-19 | エーエムプロテイン コーポレイション | キメラ治療剤 |
| JP5721432B2 (ja) | 2007-08-15 | 2015-05-20 | ノボ・ノルデイスク・エー／エス | アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン |
| MX2010011499A (es) * | 2008-04-23 | 2010-11-12 | Amgen Inc | Variantes de proproteina neutralizante de convertasa subtilisina kexina de tipo 9 (pcsk9) y sus usos. |
| WO2009143633A1 (en) | 2008-05-30 | 2009-12-03 | Institut De Recherches Cliniques De Montreal | Pcsk9 inhibitors and methods of use thereof |
| TWI516501B (zh) * | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Ｐｃｓｋ９拮抗劑類 |
| CN101993485B (zh) | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | 促胰岛素分泌肽类似物同源二聚体及其用途 |
| CN103052900A (zh) | 2010-08-02 | 2013-04-17 | 日本电气株式会社 | 偏振器和发光装置 |
| CN102153652A (zh) | 2010-12-10 | 2011-08-17 | 浙江大学 | 一种融合蛋白的表达方法及用途 |
| JP2014510516A (ja) | 2011-02-15 | 2014-05-01 | ノヴォ ノルディスク アー／エス | 長時間作用性ｉｌ−１受容体アンタゴニスト |
| WO2012177741A1 (en) * | 2011-06-20 | 2012-12-27 | Genentech, Inc. | Pcsk9-binding polypeptides and methods of use |
| AU2012311484B2 (en) * | 2011-09-23 | 2017-04-13 | Novo Nordisk A/S | Novel glucagon analogues |
| UY34347A (es) | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de función dual para tratar trastornos metabólicos |
| US20140357838A1 (en) * | 2011-12-21 | 2014-12-04 | Novo Nordisk A/S | N-Terminally Modified Insulin Derivatives |
| EP2851429B1 (en) | 2012-05-18 | 2019-07-24 | Adda Biotech Inc. | Protein and protein conjugate for diabetes treatment, and applications thereof |
| TW201420606A (zh) | 2012-08-22 | 2014-06-01 | Lilly Co Eli | 同源二聚體蛋白 |
| JP2015533483A (ja) | 2012-09-07 | 2015-11-26 | サノフイ | メタボリックシンドロームを治療するための融合タンパク質 |
| EP2986313B1 (en) * | 2013-04-18 | 2019-06-12 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| CA2935285A1 (en) | 2014-02-21 | 2015-08-27 | Medimmune, Llc | Anti-pcsk9-glp-1 fusions and methods for use |
| US10570184B2 (en) * | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
| CN104558198A (zh) | 2014-07-25 | 2015-04-29 | 成都贝爱特生物科技有限公司 | GLP-1类似物和amylin类似物的融合蛋白制备及其用途 |
| US20180207223A1 (en) * | 2015-03-19 | 2018-07-26 | Institut De Cardiologie De Montreal | Pcsk9 inhibitory polypolypeptides and methods of use |
| CN105367884A (zh) | 2015-11-02 | 2016-03-02 | 陈薇 | 一种绝缘耐火抗辐射的屏蔽电缆材料及其制备方法 |
| SI3402811T1 (sl) | 2016-01-13 | 2022-06-30 | Novo Nordisk A/S | Analogi EGF(A) z maščobnokislinskimi substituenti |
| CA3068956A1 (en) | 2017-07-19 | 2019-01-24 | Novo Nordisk A/S | Bifunctional compounds |
| MA49617A (fr) | 2017-07-19 | 2020-05-27 | Novo Nordisk As | Analogues d'egf(a), préparation, formulations et utilisations associées |
-
2017
- 2017-01-13 SI SI201731149T patent/SI3402811T1/sl unknown
- 2017-01-13 US US16/069,932 patent/US10822385B2/en active Active
- 2017-01-13 RS RS20220538A patent/RS63298B1/sr unknown
- 2017-01-13 PE PE2018001257A patent/PE20181376A1/es unknown
- 2017-01-13 CA CA3010756A patent/CA3010756A1/en not_active Withdrawn
- 2017-01-13 PL PL17701078T patent/PL3402811T3/pl unknown
- 2017-01-13 LT LTEPPCT/EP2017/050668T patent/LT3402811T/lt unknown
- 2017-01-13 BR BR112018013820-7A patent/BR112018013820A2/pt not_active Application Discontinuation
- 2017-01-13 JP JP2018536444A patent/JP6797926B2/ja active Active
- 2017-01-13 DK DK17701078.2T patent/DK3402811T3/da active
- 2017-01-13 RU RU2018127882A patent/RU2747877C2/ru active
- 2017-01-13 MY MYPI2018702319A patent/MY195199A/en unknown
- 2017-01-13 HU HUE17701078A patent/HUE058647T2/hu unknown
- 2017-01-13 WO PCT/EP2017/050668 patent/WO2017121850A1/en not_active Ceased
- 2017-01-13 ES ES17701078T patent/ES2916998T3/es active Active
- 2017-01-13 MX MX2018008681A patent/MX2018008681A/es unknown
- 2017-01-13 KR KR1020187022105A patent/KR102417487B1/ko not_active Expired - Fee Related
- 2017-01-13 HR HRP20220720TT patent/HRP20220720T1/hr unknown
- 2017-01-13 EP EP17701078.2A patent/EP3402811B1/en active Active
- 2017-01-13 CN CN201780006783.6A patent/CN108473550B/zh active Active
- 2017-01-13 AU AU2017207862A patent/AU2017207862B2/en not_active Ceased
-
2018
- 2018-06-14 IL IL260043A patent/IL260043A/en unknown
- 2018-07-09 CL CL2018001868A patent/CL2018001868A1/es unknown
- 2018-07-10 SA SA518391996A patent/SA518391996B1/ar unknown
- 2018-07-12 PH PH12018501502A patent/PH12018501502A1/en unknown
- 2018-07-16 CO CONC2018/0007440A patent/CO2018007440A2/es unknown
-
2020
- 2020-09-17 US US17/024,264 patent/US20200407409A1/en not_active Abandoned
- 2020-11-17 JP JP2020190846A patent/JP2021035989A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3402811T3 (da) | Egf(a)-analoger med fedtsyresubstituenter | |
| CY2024039I1 (el) | Pth προφαρμακα | |
| EP3870593A4 (en) | NUCLEOTIDE ANALOGUES | |
| EP3370731A4 (en) | nucleotide analogs | |
| MA42615A (fr) | Composés phosphodiamide antiviraux d'ester d'acide bêta-aminé | |
| DK3362461T3 (da) | Mrna-cap-analoger med modificeret phosphatbinding | |
| EP3328827A4 (en) | PRODRUGS OF GLUTAMINE ANALOGS | |
| DK3236782T3 (da) | Fremgangsmåde til forøgelse af stabiliteten af en sammensætning, der omfatter flerumættede omega-3-fedtsyrer | |
| MA41614A (fr) | Composés antiviraux | |
| DK3194411T3 (da) | Nukleotidanaloger | |
| MA42036A (fr) | Analogues nucléosidiques 5'-substitués | |
| DK4122954T3 (da) | Novel GLP-1-analoger | |
| EP3350191A4 (en) | nucleotide analogs | |
| DE112015001114A5 (de) | Herstellung optoelektronischer Bauelemente | |
| DK3229995T3 (da) | Fremgangsmåde for fremstilling af et endestykke | |
| EP3378546A4 (en) | REMOVABLE TOY | |
| DK3236783T3 (da) | Fremgangsmåde til forøgelse af stabiliteten af en sammensætning, der omfatter flerumættede omega-6-fedtsyrer | |
| HUE055663T2 (hu) | Készítmény lágy antikolinerg analógokhoz | |
| DK3294287T3 (da) | Oxabicycloheptan-prodrugs | |
| DK3116854T3 (da) | Ny fremgangsmåde til fremstilling af prostaglandiner med høj renhed | |
| HUE055293T2 (hu) | Szerkezet alkatrészen való rögzítéshez | |
| HRP20181916T1 (hr) | Postupci pripreme oksitocinskih analoga | |
| FI20150044A7 (fi) | Rasvahappokoostumus | |
| EP3400237A4 (en) | Peptide analogs | |
| EP3906225C0 (en) | Pantothenamide analogues |